$LLY

HR8032 ensures equitable Medicare payment for cancer treatments, directly benefiting pharmaceutical companies and biotech firms focused on oncology. This bill stabilizes revenue streams for cancer drug manufacturers within the outpatient setting.

The National Plan for Epilepsy Act (S494) establishes a national strategy for epilepsy research and care. This bill directs federal agencies to coordinate efforts, potentially increasing funding for research and treatment development, benefiting pharmaceutical and biotechnology companies focused on neurological disorders.

The Endless Frontier Act (HR6978) establishes a new directorate within the National Science Foundation (NSF) to fund R&D in critical technology areas, directly benefiting U.S. technology and manufacturing companies. This bill allocates significant federal funds to bolster domestic innovation and competitiveness, creating a direct revenue stream for companies involved in semiconductor manufacturing, artificial intelligence, and biotechnology. The bill's referral to committee indicates initial legislative movement.

The PASTEUR Act aims to create a subscription-style payment model for novel antibiotics, decoupling drug value from sales volume. This bill, if passed, will stabilize the market for antibiotic development, directly benefiting pharmaceutical companies focused on infectious disease research.

The PASTEUR Act establishes a subscription-style payment model for novel antibiotics, guaranteeing revenue for pharmaceutical companies developing new antimicrobial treatments. This de-risks R&D for antibiotics, driving investment and innovation in a critical healthcare area. Companies with strong antibiotic pipelines stand to gain significant, predictable revenue streams.

The Immediate Access for the Terminally Ill Act accelerates patient access to experimental drugs, increasing revenue opportunities for pharmaceutical companies with late-stage clinical pipelines. This bill directly expands the market for investigational therapies by reducing regulatory hurdles.

The Treat and Reduce Obesity Act of 2025 expands Medicare coverage for obesity treatments, directly benefiting pharmaceutical companies producing GLP-1 agonists and medical device manufacturers. This legislation significantly increases the total addressable market for these therapies.

The 'Skinny Labels, Big Savings Act' directly targets brand-name pharmaceutical companies by limiting their ability to block generic competition. This legislation will reduce drug prices and significantly decrease revenue for innovator drug manufacturers, while benefiting generic drug producers.